Explore the vast range of titles available.

We present a multimode X -band rf pulse compression system suitable for a TeV-scale electron-positron linear collider such as the Next Linear Collider (NLC). The NLC main linac operating frequency is 11.424 GHz. A single NLC rf unit is required to produce 400 ns pulses with 475 MW of peak power. Each rf unit should power approximately 5 m of accelerator structures. The rf unit design consists of two 75 MW klystrons and a dual-moded resonant-delay-line pulse compression system that produces a flat output pulse. The pulse compression system components are all overmoded, and most components are designed to operate with two modes. This approach allows high-power-handling capability while maintaining a compact, inexpensive system. We detail the design of this system and present experimental cold test results. We describe the design and performance of various components. The high-power testing of the system is verified using four 50 MW solenoid-focused klystrons run off a common 400 kV solid-state modulator. The system has produced 400 ns rf pulses of greater than 500 MW. We present the layout of our system, which includes a dual-moded transmission waveguide system and a dual-moded resonant line (SLED-II) pulse compression system. We also present data on the processing and operation of this system, which has set high-power records in coherent and phase controlled pulsed rf.

Pharmaceutical risk management can be considered to be any strategies for minimizing risks and enabling the realization of the benefits of medications. Historically, risk management has been achieved through the drug label, which includes the US Controlled Substances Act (CSA) drug scheduling placement if abuse and dependence are considered sufficiently serious to warrant special restrictions. Since the late 1990s, additional strategies for addressing abuse- and dependence-related risks have been developed, including various postmarketing requirements for surveillance and reporting to the Food and Drug Administration. These strategies have been described in guidance documents and include risk assessment, risk management, and postmarketing surveillance. Preclinical abuse potential assessment provides early signals of potential risks and scheduling. Such studies are also considered in the premarket risk evaluation that guides recommendations concerning risk management strategies that go beyond drug scheduling along with the evaluation of abuse-deterrent drug products and how such evaluation might be informed by preclinical studies.